explore -WSS

explore

author：explore 2025-09-27 13:03:26 - browse：675

a photo of the federal trade commission building — Alex Brandon/AP

The federal government is suing to block a proposed hospital deal in North Carolina, alleging it would hand control of over 65% of the inpatient market in the region to a single provider.

Novant Health’s proposed acquisition of two nearby hospitals is precisely the kind of case antitrust experts would expect the Federal Trade Commission to take on because it would make an already large regional player, Novant, even more powerful. And even though smaller deals like this get less attention than huge, 100-plus hospital mergers, they can still drive up people’s insurance premiums and medical bills.

In this case, Novant, a nonprofit system with $7.6 billion in 2022 revenue, plans to buy two hospitals in the same county from the for-profit chain Community Health Systems for $320 million. The two hospitals, Lake Norman Regional Medical Center and Davis Regional Medical Center, are only about a 25-minute drive from one another. A Novant spokesperson called the FTC’s position flawed and said the system will pursue available legal responses. CHS spokesperson Tomi Galin wrote in an email that a judge will make the final determination on whether the transaction can proceed and thanked staff for continuing to deliver quality care during the regulatory process.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Why don't Americans have at

WSS

Why don't Americans have at

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Some top drug companies are starting to take action on climate

Study points to new risk in gene therapy death of Terry Horgan

Juul documents reveal insider tactics on political lobbying

focus

explore

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

With Roe v Wade overturned, abortion providers work to adapt

Medicare details structure of new drug price negotiation program

ACIP vaccine advisory panel sees its vacancies filled

Psychedelics group wrestles with new pharma identity

European officials brace for rough respiratory virus season

The cancer drug shortage isn’t new — and neither are the solutions

New oral drug delivery patch is modeled after octopus tentacles

Activists slam private health insurers over coverage restrictions

Study points to new risk in gene therapy death of Terry Horgan

focus

WHO recommends second malaria vaccine

Study points to new risk in gene therapy death of Terry Horgan

Congress extends some pandemic preparedness programs

Study points to new risk in gene therapy death of Terry Horgan

RSV injection headlines need to be accurate for good uptake

Setback for rare diseases as Taysha Gene Therapies pulls back

Wikipedia

hotspot

focus

hotspot